Ann Dermatol.  2026 Aug;38(4):320-328. 10.5021/ad.25.222.

Efficacy and Safety of Alitretinoin for Chronic Hand Eczema: A Meta-Analysis

• Lee YJ
• Lee JM
• Choi YJ
• Han TY
• Choi JE
• Han B
• Pyo JS
• Lee JH

• KMID: 2583754
• DOI: http://doi.org/10.5021/ad.25.222

Abstract

Background
Hand eczema is a common inflammatory dermatosis that can severely impair quality of life. Chronic or refractory cases often require systemic therapy. Alitretinoin, a vitamin A derivative, is approved for patients unresponsive to potent topical corticosteroids.
Objective
This meta-analysis aimed to evaluate its efficacy and safety in chronic hand eczema.
Methods
A PubMed search up to April 10, 2023, identified relevant studies. Outcomes included therapeutic response, adverse events, and laboratory changes. Efficacy was assessed using Physician Global Assessment (PGA), Patient Global Assessment (PaGA), and modified Total Lesion Symptom Score (mTLSS). Subgroup analyses by dosage and treatment duration, with meta-regression, were performed.
Results
Twenty-four studies were included. Overall improvement rates were 47.8% for PGA and 36.4% for PaGA, with greater benefit observed in PGA. Higher dosages produced superior efficacy in both PGA and PaGA, and meta-regression confirmed significant differences between 10 mg and 30 mg groups. Longer treatment in 30 mg subgroup was associated with better outcomes for PGA, PaGA, and mTLSS. Adverse events occurred in 48.3% of cases, most commonly headache, skin fissure, back pain, and dry eye. Triglyceride elevation was the most frequent laboratory abnormality.
Conclusion
Alitretinoin showed favorable efficacy in chronic hand eczema. Consistent with previous studies, we observed a trend of increasing efficacy with higher dosages. Furthermore, at high dosage, greater efficacy was observed with longer durations of use. Adverse events were generally tolerable, supporting its role as a therapeutic option in refractory cases.

Keyword

Alitretinoin; Eczema; Hand; Meta-analysis